Skip to content

Advertisement

Open Access

Unravelling the patterns of host immune responses in Plasmodium vivax malaria and dengue co-infection

  • Vitor R R Mendonça1, 2,
  • Bruno B Andrade1,
  • Ligia C L Souza1, 2,
  • Belisa M L Magalhães3, 4,
  • Maria P G Mourão3, 4,
  • Marcus V G Lacerda3, 4 and
  • Manoel Barral-Netto1, 2, 5Email author
Malaria Journal201514:315

https://doi.org/10.1186/s12936-015-0835-8

Received: 24 June 2015

Accepted: 4 August 2015

Published: 14 August 2015

Abstract

Background

Concurrent malaria and dengue infection is frequently diagnosed in endemic countries, but its immunopathology remains largely unknown. In the present study, a large panel of cytokines/chemokines and clinical laboratory markers were measured in patients with Plasmodium vivax and dengue co-infection as well as in individuals with malaria or dengue mono-infections in order to identify biosignatures of each clinical condition.

Methods

Individuals from the Brazilian Amazon were recruited between 2009 and 2013 and classified in three groups: vivax malaria (n = 52), dengue (n = 30) and vivax malaria and dengue co-infection (n = 30). P. vivax malaria was diagnosed by thick blood smear and confirmed by PCR; dengue cases were detected by IgM ELISA or NS1 protein. The plasma levels of cytokines and chemokines were determined by multiplex assay.

Results

Individuals with malaria and dengue co-infection displayed lower levels of platelets and haemoglobin than those with malaria or dengue mono-infections (p = 0.0047 and p = 0.0001, respectively). The group of individuals co-infected exhibited the highest median concentrations of IFN-γ, IL-6, CCL4 than the mono-infected groups. Network analyses of plasma cytokines/chemokines revealed that malaria and dengue co-infection exhibits a distinct immune profile with critical roles for TNF, IL-6 and IFN-γ. Further, parasitaemia levels displayed positive significant interactions with IL-6, CCL4 and IL-10 in the group of patients co-infected with malaria and dengue. No differences were observed in distribution of dengue virus serotypes and Plasmodium parasitaemia levels between the groups.

Conclusions

The findings described here identify unique patterns of circulating immunological markers in cases of malaria and dengue co-infection and provide insights on the immunopathology of this co-morbid condition.

Keywords

Immune responseCo-infectionDengue Plasmodium vivax Malaria

Background

Malaria and dengue fever are the most frequent arthropod-borne diseases in the world. Every year Plasmodium infection is responsible for around one million deaths, mainly in children [1]. It is estimated that two-fifths of the world population are at risk of dengue fever with 50–100 million cases each year worldwide [2, 3]. Both malaria and dengue fever exhibit dramatically similar geographic distribution (mostly in tropical and sub-tropical regions) and the detection of patients with concurrent malaria and dengue infections is not rare [419].

Previous studies have reported a frequent presence of malaria and dengue co-infections in different countries and implied that this fact creates challenges for reliable clinical diagnosis due to the overlap of major symptoms with malaria or dengue mono-infections [4, 68, 11, 12, 14, 16]. Recently, observations from a case series of patients with dual malaria and dengue infections performed at the Brazilian Amazon indicated that co-infection can potentially result in a more severe disease presentation [10]. The status of host immune activation profile in patients with dengue and malaria co-infection, which may explain the clinical features of this condition, has not been systematically investigated.

The immunopathogeneses of dengue and malaria display common features, which include the production of multiple cytokines and the balance between pro-inflammatory and anti-inflammatory responses may regulate the clinical spectrum of these infections [2025]. Importantly, circulating cytokines as well as other inflammatory mediators may be used as biomarkers for an early diagnosis or for prediction of unfavourable clinical deterioration and poor prognosis or treatment responses [26]. Moreover, understanding the key factors associated with increased morbidity may lead to development of host-directed therapy focused on the modulation of pathological immune responses and better clinical prognosis. The present study performs for the first time a detailed exploratory description of the systemic immune profile of individuals presenting with Plasmodium vivax malaria and dengue co-infection as well as in subjects with P. vivax or dengue mono-infections.

Methods

Study design and participants

Outpatients with an acute febrile syndrome who sought care in a reference hospital (Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, FMT-HVD) in Manaus, in the Brazilian Amazon, were recruited between 2009 and 2013. Malaria individuals were diagnosed by blood thick smear and those with P. vivax confirmed by PCR were recruited. Dengue subjects were diagnosed by: NS1 and RT PCR (Kit Platelia™ Dengue NS1 Ag, Bio-Rad, France) in individuals with fewer than 6 days of fever, or by the detection of IgM ELISA as descrided by Kuno et al. [27] in individuals with more than 7 days of fever. All dengue-positive individuals were recruited and had the identification of virus serotype by RT PCR. Co-infected subjects with P. vivax malaria and dengue were also recruited. All patients with microscopic or molecular diagnosis of malaria caused by Plasmodium falciparum or P. vivax and P. falciparum co-infection (mixed infection), patients with serologic diagnosis of viral hepatitis (A, B, C, and D), HIV, and leptospirosis were excluded. Patients with complications of dengue or malaria according to WHO criteria [28] were excluded from this study. All malaria cases were treated following the guidelines of the National Foundation of Health, Brazil, with chloroquine for three days and primaquine (0.5 mg/kg/day) for 7 days. Dengue patients were treated according to their symptomatology. No individuals were treated for malaria or/and dengue 30 days before the blood collection and participation in this study.

Ethics statement

All clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki. Written informed consent was obtained from all participants before enrolling into the study. This study was approved by the Ethics Committee of the FMT-HVD (protocol numbers: 2009/15243 and 39163/2012).

Plasma measurements

Blood was obtained by venopuncture at the study enrolment and heparinized plasma was separated by centrifugation and stored at −70 °C until use in immunoassays. Circulating levels of several cytokines and chemokines, including IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-17, IFN-γ, TNF, CCL2, CCL4, GCSF, GMCSF, were measured using a single multiplex assay according to the manufacturer’s protocol (BIO-RAD, Hercules, CA, USA). The clinical laboratory markers haemoglobin (HB), haematocrit (HT), platelets (PTL), aspartate amino-transferase (AST) and alanine amino-transferase (ALT) were measured in fresh plasma/serum samples at the Clinical Laboratory facility from the FMT-HVD (Manaus, Brazil).

Network analysis

The inferential networks were generated from Spearman correlation matrices containing values of each biomarker measured in the plasma samples. The values were input in JMP 10.0 software (SAS, Cary, NC, USA). Each mediator is selected as a target, and the software performs a search within the other mediators for those that are correlated, with the target calculating a correlation matrix using Spearman rank tests. As a result, the features related to the selected target are linked. The links shown in the networks represent statistically significant Spearman rank correlations (P < 0.05). In order to analyse the structure of the biomarker networks, the network density was calculated, which is, in the context of this study, the ratio of the number of edges inferred in the network over the total number of possible edges between all pairs of nodes [24]. The density measure is defined as follows: density = L/(N (N − 1)/2), in which L is the number of observed edges (i.e., Spearman correlations with P < 0.05) and N is the total number of the nodes in the network. The density is normalized, ranging between 0 (no edges in the network) and 1 (all possible edges present). The networks figures were customized using the Ingenuity Systems Pathway Analysis software (Ingenuity Systems, Redwood City, CA, USA) and Adobe Illustrator (Adobe Systems Inc.).

Data analysis

In the exploratory analysis of the data, frequency tables were constructed and the Chi square test was applied to evaluate the association between categorical variables. The continuous variables were tested for Gaussian distribution within the total sample using D’Agostino and Pearson omnibus normality test. All variables were not under normal distribution, and non-parametric tests were used instead. In this context, Kruskal–Wallis with Dunn’s multiple comparison (when three groups were compared) or Mann–Whitney tests (when two groups were compared) were used to assess the differences between the clinical groups. Multinomial regression analyses adjusted for age and gender were performed to test associations between the laboratory measures (below or above the median values of the entire study population) and the different clinical conditions evaluated (malaria, dengue or co-infection). A hierarchical cluster analysis using the Ward’s method was performed to test if a combination of different immune-related biomarkers could cluster the study groups separately. The statistical analyses were performed using the programs GraphPad Prism 6.0 (GraphPad Software Inc., USA), SPSS 19.0 (IBM, Armonk, NY, USA) and JMP 11.0 (SAS, Cary, NC, USA). A p value lower than 0.05 was considered statistically significant.

Results

Characteristics of the study participants

After clinical and microbiological assessments, individuals were grouped as vivax malaria (n = 52), dengue (n = 30) and co-infected vivax malaria/dengue (n = 30). Most participants from the malaria group were male (80.77 %, n = 42) while the groups of co-infected and dengue patients exhibited a predominance of females (70.00 %, n = 9 for both; p < 0.0001). There were no differences with regard to age between the groups (p = 0.0724; Table 1) and also no statistically significant discrepancy in parasitaemia levels between the groups of individuals infected with P. vivax (p = 0.4912; Table 1). Moreover, the majority of individuals infected with dengue had DENV2 serotype with no differences in distribution of virus serotypes in the groups of individuals with dengue or dengue and malaria co-infection (Table 1).
Table 1

Demographic characteristics and laboratory measures of the participants

 

Malaria

Co-infection Mal/Deng

Dengue

P value

(n = 52)

(n = 30)

(n = 30)

All groups

Malaria vs. co-infection

Dengue vs. co-infection

Male-no. (%)

42 (80.77)

09 (30.00)

09 (30.00)

<0.0001a

<0.0001a

1.000a

Median (IQR) age (year)

36.00 (26.25–43.75)

31.11 (20.80–44.74)

42.50 (30.00–52.25)

0.0724b

0.4471b

0.0574b

Median (IQR) of parasitaemia (parasites/uL)

3,022 (985.2–9,313)

4,262 (1,595–12,199)

0.4912b

Dengue serotypes-no. (%)

 DENV1

 

3 (10.00)

1 (3.33)

0.2247a

 DENV2

 

18 (60.00)

21 (70.00)

 DENV3

 

1 (3.33)

4 (13.33)

 DENV4

 

8 (26.67)

4 (13.33)

Median of laboratory measures (IQR)

 Haemoglobin (g/dL)

13.20 (12.50–14.20)

12.95 (11.90–14.45)

15.00 (13.40–15.95)

0.0047b

0.4819b

0.0038b

 Haematocrit (%)

43.35 (40.43–45.98)

42.05 (37.80–45.98)

43.90 (40.65–46.90)

0.5803b

0.3732b

0.3817b

 Platelets (by mm3)

102,000 (65,000–131,500)

87,500 (59,000–114,250)

186,500 (124,000–229,750)

0.0001b

0.1079b

<0.0001b

 AST (IU/L)

67.50 (50.00–91.00)

47.00 (31.50–72.50)

47.00 (28.00–147.00)

0.0186b

0.0048b

0.9315b

 ALT (IU/L)

33.00 (20.00–49.75)

69.00 (46.00–95.50)

67.00 (29.50–119.00)

<0.0001b

 < 0.0001b

0.9043b

IQR interquantile range.

aCategorized variables were compared using Chi square test or Fisher exact test.

bContinuous variables were compared using Mann–Whitney for two groups or Kruskal–Wallis test with Dunn’s multiple comparison test for three groups or more.

Differential expression of clinical laboratory parameters reveals unique patterns of associations with infection status

Univariate analyses revealed that individuals co-infected with malaria and dengue exhibited lower levels of HB and PTL than those with malaria or dengue mono-infections (p = 0.0047 and p = 0.0001, respectively; Table 1). On the other hand, plasma AST levels were elevated whereas ALT concentrations were decreased in individuals with malaria mono-infection compared to those with dengue or co-infection (p = 0.0186 and p < 0.0001, respectively; Table 1). Multinominal regression analyses adjusted for age and gender uncovered that higher levels of HB (adjusted OR: 23.344 95 % CI 2.534–215.023, p = 0.005) and PTL (adjusted OR: 8.065 95 % CI: 1.527–42.612, p = 0.014) were associated with dengue when compared to malaria (Fig. 1). Furthermore, higher levels of HB (adjusted OR: 6.264 95 % CI 1.535–25.553, p = 0.011) and PTL (adjusted OR: 21.471 95 % CI 3.077–149.827, p = 0.002) were associated with dengue mono-infection compared with dengue and malaria co-infection (Fig. 1). Higher levels of AST (unadjusted OR: 3.030 95 % CI 1.160–7.914, p = 0.024) and low levels of ALT (adjusted OR: 0.219 95 % CI 0.069–0.695, p = 0.010) were associated with malaria mono-infection compared with the malaria/dengue co-infection condition (Fig. 1).
Figure 1
Fig. 1

Discrimation of malaria, dengue and co-infection groups by laboratory measures. Differentiation between dengue vs malaria, dengue vs co-infection and malaria vs co-infection groups were done by laboratory measures—HB haemoglobin, HT haematocrit, PTL platelets, AST aspartate aminotransferase, ALT alanine aminotransferase—through multinominal regression analysis with calculation of odds ratios (OR) and 95 % confidence intervals (CI), represented by the icons and bars, respectively (a). Red icons represent OR adjusted for age and gender and blue icons were unadjusted (univariate) (a).

Networking the immune response

A panel of 17 cytokines and chemokines was used to build networks demonstrating the interactions between the candidate biomarkers in each group (Fig. 2a). The distributions of plasma concentrations of each cytokine or chemokine amongst the different clinical groups are provided (see Additional file 1). The network analysis revealed an absence of negative correlations between the candidate biomarkers in each one of the clinical groups and only statistically significant positive correlations were detected (Fig. 2a). Strikingly, the densities of the networks from each clinical group were dramatically different (Fig. 2a). The group of malaria mono-infection exhibited highest density of interactions (network density: 0.661) followed by the groups of co-infected patients (network density: 0.4338) and dengue mono-infection (network density: 0.147) (Fig. 2a). P values and Spearman rank values for each correlation between the immune biomarkers according to study groups are detailed (see Additional file 2). Moreover, the simultaneous assessment of several immune-related markers revealed relative differences in plasma concentrations that resulted in unique biosignatures, which could highlight differences between the study groups in an hierarchical cluster analysis (Fig. 2b). Amongst the clinical groups evaluated, the group of individuals with malaria and dengue co-infection exhibited the highest median concentrations of IFN-γ, IL-6, CCL4 (Fig. 2b). The group of malaria mono-infected patients exhibited a biosignature composed by higher levels of IL-10 and CCL2 whereas the group of dengue mono-infected individuals displayed a signature with high expression of IL-4, IL-7 and Il-12 in plasma (Fig. 2b). Furthermore, TNF was found elevated in both groups of malaria mono-infection and co-infection with dengue whereas IL-13 was detected in higher amounts in the groups of dengue mono-infection and co-infection (Fig. 2b). While investigating the relationships between changes in clinical laboratory markers and the inflammatory environment assessed by network densities, it was observed that HB, PTL and ALT displayed a general trend to decrease in concentration values according to the increase of network’s complexities (Fig. 2c). Nevertheless, AST levels tended to increase following the density of correlations between the markers in the groups (Fig. 2c). No significant difference was observed in variations of HT levels and its associations with network densities (Fig. 2c).
Figure 2
Fig. 2

Networks of candidate immune-related biomarkers during malaria, dengue or co-infection. Plasma levels of several immune-related (cytokines, chemokines) biomarkers were measured in malaria, dengue and co-infection subjects. Each connecting line represents a significant interaction (P < 0.05) detected by Spearman’s correlation test (a). All interactions had positive correlations. A heat map was designed to depict the overall pattern of expression of immune markers in the different outcomes by the median value of each parameter (b). A two-way hierarchical cluster analysis (Ward’s method) of immune molecules by clinical group was performed (b). Biomarkers that had the same median in the three groups were excluded from the heat map and cluster analysis. The colours shown for each symbol represent the fold variation from the median values calculated for each marker (a, b). The distribution of haemoglobin (HB), haematocrit (HT), platelets (PTL), aspartate aminotransferase (AST), alanine aminotransferase (ALT) in different clinical groups is shown in red symbols (medians and interquartile ranges) whereas the values for network densities are shown as black bars (c). The variation of HB, HT, PTL, AST, and ALT according to the groups was assessed using the Kruskal–Wallis test (***P < 0.001; **P < 0.01; *P < 0.05; ns = non-significant) (c). The five immune-related biomarkers with the highest number of interactions in all three groups were chosen (IFN-γ, IL-6, IL-13, TNF, and IL-12) and the relative number of interactions of these biomarkers was calculated according to each group (d). Dark grey rectangles represent the highest relative number of connections, light grey rectangles the medium relative number and white rectangles the lowest relative number of hits between molecules (d).

Amongst the 17 immune-related biomarkers assessed in the network analyses, five cytokines exhibited the highest number of interactions (statistically significant Spearman correlations) when all the study groups were considered together: IFN-γ (participated in 7.40 % of all interactions), IL-6 (8.88 % of all interactions), IL-13 (7.10 % of all interactions), TNF (6.50 % of all interactions) and IL-12p70 (6.50 % of all interactions) (Fig. 2d). In order to assess if the number of network connections involving each one of these five cytokines could highlight differences between the clinical groups, the percentage of edges involving with each molecule related to the overall number of edges in the network was calculated. Interestingly, IFN-γ, IL-6 and IL-13 displayed the highest relative number of network interactions in the group of dengue mono-infected patients, whereas IL-12p70 exhibited the highest relative number of interactions in the malaria mono-infection group (Fig. 2d). TNF exhibited the highest number of interactions in the group of patients with malaria and dengue co-infection (Fig. 2d). These results argue that unique immune signatures involving plasma cytokine levels are able to highlight differences that distinguish malaria, dengue or dual malaria and dengue infection.

The next step was to uncover the interactions between clinical laboratory markers and the immune-related molecules. In all the study groups, HB exhibited positive associations with HT whereas ALT exhibited positive correlations with AST (Fig. 3a). It was found that HB and HT displayed several negative significant interactions mainly with IL-4, IL-5, IL-12p70, and IL-17, whereas ALT interacted negatively with IL-4 and IL-7 in the malaria group (Fig. 3a). In the group of patients with malaria and dengue co-infection, HB and HT displayed negative associations with IL-7, whereas AST exhibited positive interactions with CCL2, IL-13 and IL-8 (Fig. 3a). Noteworthy, it was observed that only in the dengue mono-infection group did PTL display interactions with immune markers (positive interactions with GMCSF, GCSF and IL-8), suggesting a major role for this molecule in this group (Fig. 3a). Furthermore, AST and ALT displayed negative associations with TNF in the network of the dengue mono-infection group (Fig. 3a). In the P. vivax-infected groups, the associations between parasitaemia and the immune markers were also studied (Fig. 3b). It was observed that P. vivax parasitaemia displayed positive significant interactions with IL-6, CCL4 and IL-10 in the group of patients co-infected with malaria and dengue, while this parameter exhibited several positive correlations with many immune markers (GCSF, CCL2, CCL4, TNF, IL-12p70, IL-10, IL-6, and IL-4) in the group of malaria mono-infected subjects, suggesting a major role for parasitaemia in the immune profile in this clinical condition (Fig. 3b). P values and Spearman rank values for each correlation between the immune biomarkers and laboratory measures or parasitaemia are provided (see Additional file 3).
Figure 3
Fig. 3

Associations between laboratory parameters, parasitaemia and immune-related biomarkers. Statistically significant correlations between laboratory markers (a) or parasitaemia (b) and immune-related biomarkers are shown for the different groups. The correlations were assessed using the Spearman rank test. The interactions involving parasitaemia shown in (c) are plotted on top of the host interactome. Green lines represent negative significant (P < 0.05) correlations and orange lines, positive significant correlations.

Discussion

Malaria or dengue immunology has been studied extensively in a diverse range of scenarios, however, the profile of the immune responses in individuals co-infected with Plasmodium and dengue virus has not been systematically explored. In the present study, a large panel of cytokines and chemokines as well as several clinical laboratory markers used to assess degree of disease severity and inflammation-driven tissue damage have been investigated in plasma samples of patients with malaria, dengue or co-infection in order to identify immune signatures associated with each infection status. Network analyses revealed that cases of malaria and dengue co-infection exhibit a unique immune profile with a special role for TNF, IL-6, IFN-γ, and IL-7. In addition, the analysis herein further revealed a signature profile in which P. vivax parasitaemia levels display positive significant interactions with IL-6, CCL4 and IL-10 in patients with this co-infection, which was not observed in malaria mono-infected individuals.

Some studies have studied laboratory measurements in subjects with dual malaria and dengue infections [4, 6, 11]. HB and PTL are usually shown to be decreased in individuals co-infected with malaria and dengue and AST has been shown to be higher in individuals with malaria compared with co-infected cases [4, 6, 11]. These findings are similar to the results described in the present study. When dengue was compared to malaria mono-infection or co-infected cases, the former had higher values of HB and PTL. Malaria infection is frequently associated with anaemia as its causative parasite has a blood stage and causes intense intravascular haemolysis. One major complication associated with both dengue and malaria disease is thrombocytopaenia and the findings from the present study indicate that P. vivax infection may cause more severe thrombocytopaenia (with lowest values in co-infected cases) compared to dengue fever mono-infection [2931]. Other studies have also reported that platelet counts were lower in malaria patients than dengue patients [15, 32]. On the other hand, laboratory markers assessed in the current study showed similar values between malaria mono-infection and cases of malaria and dengue co-infection, with a major difference in ALT levels (and in less extension to AST), which were more elevated in the patients with co-infection, and no significant difference was observed in parasitaemia levels. The relationship of AST and ALT and parasitaemia with clinical manifestations of mono- or co-infection of malaria and dengue is not well established. A previous study showed higher levels of AST and ALT and parasitaemia in malaria mono-infection compared to malaria and dengue co-infection [11]. Nevertheless, another report showed no differences in concentrations of AST and ALT as well as levels of parasitaemia between malaria mono-infected patients and those with malaria and dengue co-infection [6]. Differences in patient populations and parasite strains could explain these discrepancies. Parasitaemia levels may have an important role in predicting hepatic damage and need to be considered in malaria-infected subjects [25].

Heightened levels of TNF and IFN-γ have been systematically associated with increased clinical disease severity in malaria or dengue fever in many case series [20, 21, 24, 25, 3335]. An important role for TNF and IFN-γ in the onset of malaria symptomatology as well as in pathological processes associated with platelet consumption, endothelial cell activation and haemorrhagic manifestations during dengue fever have been described previously [33, 36]. In the present study, increased TNF levels observed in the group of patients with malaria and dengue co-infection compared to malaria or dengue mono-infections, together with the significantly higher number of interactions in the cytokine/chemokine networks, argue that this cytokine may play a critical role in the pathogenesis of malaria and dengue fever comorbid condition. Noteworthy, TNF polymorphisms are common and may play a role in TNF levels in the context of malaria [37]. Moreover, amongst the clinical groups assessed herein, cases of malaria and dengue co-infection also exhibited the highest values of IFN-γ and IL-6. IL-6 has been implicated in the pathogenesis of severe cases of dengue as this cytokine enhances the production of anti-platelet or anti-endothelial cell auto-antibodies, as well as the induction of tissue plasminogen activator, leading to increased risk for bleeding [38, 39]. These findings on immune markers support the idea that co-infected cases may present with a more severe inflammation milieu and disease status compared to malaria or dengue mono-infections. Recently, it has been described that individuals with concurrent dengue fever and malaria from the Brazilian Amazon and French Guiana exhibited more severe disease clinical presentation than mono-infections [6, 9, 10].

In the present study, plasma levels of IL-4, IL-7, IL-12p70, and IL-13 were more elevated in subjects purely with dengue fever than in those with malaria mono-infection or malaria and dengue co-infection. Noteworthy, IL-12p70 has been previously associated with severity and protection during malaria [4043], also polymorphism in this gene can influence this cytokine production during malaria [44]. IL-12p70 had the highest number of interacions in the malaria group and seems to influence the inflammatory milieu in this group. In addition, IL-13 had the highest relative number of interactions in the cytokine/chemokine network of the group of dengue mono-infection. IL-4 and IL-13 plasma levels were also previously found to be higher in dengue fever compared to malaria cases [23]. The increase in plasma expression of Th2 cytokines (i.e., IL-4, IL-13) may be associated with augmentation of vascular permeability and vascular leakage as seen in dengue haemorrhagic fever [45, 46]. Regarding malaria mono-infection, IL-10 and CCL2 were the immune markers with more relevant elevations in plasma. Maneekan et al. have described that IL-10 was statistically higher in malaria patients than in those with dengue fever [23]. Furthermore, IFN-γ/IL-10 ratio has been reported to increase proportionally to malaria clinical severity [25], and it is possible that cases of malaria and dengue co-infection presenting with lower levels of IL-10 and higher levels of IFN-γ may be reflected in an increased disease severity. Further studies, including a broader clinical spectrum of the infections explored here, are necessary to address this question. In a study about the immune profile of dengue fever and parvovirosis, high levels of CCL2 tended to be associated with parvovirus B19 infection as the same way as observed herein with malaria infection [47]. Therefore, different infectious agents disease may stimulate specific features of the host immune responses, which may result in unique immune signatures.

Although the group of individuals co-infected with malaria and dengue displayed an intermediate density of the immune network compared to the other clinical groups, this group displayed the lowest values of HB and PTL, thus indicating that the relationships between the inflammatory markers may not be influenced directly by the levels of these clinical laboratory markers. However, a potential role for HB and HT in regulation of the inflammatory environment in malaria and dengue comorbidity could not be entirely discarded, and the network findings indicate that these parameters were negatively correlated with IL-7 in this group. It has been reported that IL-7 plays an important role in CD4+ T cell immune responses against the dengue virus and this cytokine is also useful for maintaining the growth and antigen-specific cytotoxic activity of CD4+ human cytotoxic T lymphocyte clones [48]. In addition, AST seemed to be highly influenced by immune molecules in the malaria and dengue co-infected patients as this enzyme was positively correlated with CCL2, IL-13 and IL-8.

In the context of laboratory and immune markers correlations, the group of individuals presenting with malaria mono-infection displayed significant negative correlations between ALT and IL-4 and IL-7. Liver enzymes are highly inducible by the activation of immune responses and ALT was also correlated with TNF and superoxide dismutase-1 (SOD-1) levels in another case series of vivax malaria [49]. Furthermore, HB and HT had several negative interactions with inflammatory mediators (IL-17, IL-12, IL-5, IL-4) in the malaria group. These interactions may be explained as HB and HT levels as well as the immune response are directly influenced by intravascular haemolysis of red blood cell rupture upon Plasmodium sp. replication. Noteworthy, PTL positively interacted with immune markers (GCSF, GMCSF and IL-8) only in the group of patients with dengue mono-infection. It has been reported that exposure of monocytes from healthy volunteers to platelets from patients with dengue induced the secretion of IL-8 [50]. Thrombocytopaenia is often described in dengue fever (about of 23.6 % of cases) and it may play a role along with immune mediators in dengue immunopathology [51].

Parasitaemia was not different between the groups of individuals with malaria mono-infection and malaria and dengue co-infection, similarly to previous studies [6]. However, the network analysis uncovered that parasitaemia displayed more statistically significant interactions with cytokines/chemokines in the malaria mono-infection than in the group of co-infected patients. The immune response of individuals with concurrent dengue and malaria infections is also influenced by dengue viruses and this may explain the lower number of interactions of parasitaemia in this group. Moreover, one limitation of the present report was that some co-infected individuals could have had undiagnosed asymptomatic malaria, which can sometimes be diagnosed only with molecular methods. It is well described that asymptomatic malaria individuals control parasitaemia to very low levels (sometimes only detectable by molecular techniques) and this clinical immunity results in a reduced intensity of the inflammatory response when compared to symptomatic malaria cases [24, 25].

Conclusion

Altogether, the findings of the present study indicate that concurrent malaria and dengue infections may cause a more severe disease compared to mono-infections as observed by laboratory and immune markers profiles. Overall, malaria and dengue co-infection displayed lower levels of platelets and haemoglobin and a specific immune signature with a special role for TNF compared to dengue or malaria. This detailed description of the immune response profile in subjects with malaria and dengue fever co-infection and the results depicted herein shed light into the immunopathology of this comorbid condition. Further prospective studies with larger samples and experimental models would be necessary to investigate the key mechanisms resulting in the biosignatures identified here in patients with malaria and dengue co-infection.

Abbreviations

FMT-HVD: 

Fundação de Medicina Tropical Dr Heitor Vieira Dourado

PCR: 

polymerase chain reaction

NS1: 

non-structural protein 1

RT PCR: 

real-time polymerase chain reaction

IgM: 

immunoglobulin M

ELISA: 

enzyme-linked immunosorbent assay

HIV: 

human immunodeficiency virus

WHO: 

World Health Organization

IL-: 

interleukin

IFN: 

interferon

TNF: 

tumour necrosis factor

CCL2: 

chemokine C–C motif ligand 2

CCL4: 

chemokine C–C motif ligand 4

GCSF: 

granulocyte colony stimulating factor

GMCSF: 

granulocyte macrophage colony stimulating factor

HB: 

haemoglobin

HT: 

haematocrit

PTL: 

platelets

AST: 

aspartate transaminase

ALT: 

alanine transaminase

DENV: 

dengue virus

OR: 

odds ratio

CI: 

confidence interval

CD: 

cluster of differentiation

SOD-1: 

superoxide dismutase 1

Declarations

Authors’ contributions

VRRM performed the experiments, analysed the data, and wrote the manuscript together with BBA and MBN. LCLS helped perform the experiments. BMLM was responsible for the field study and sampling. MVGL and MPGM supervised the clinical study and sampling in Manaus. MBN conceptualized the study, and helped with data interpretation and the writing of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The authors thank the research team at FIOCRUZ-Bahia, Brazil, Jorge Tolentino, Adorielze Leite, Nataly Alexandrino and Andrezza Kariny for help in logistics; and to Patricia Bozza and Edson Assis at FIOCRUZ-RJ for help in the multiplex assay experiment.

This work was supported by FIOCRUZ and FMT-HVD. MBN, MVGL and MPGM are senior investigators from Conselho Nacional de Pesquisa e Tecnologia (CNPq), Brazil. VRRM, LCLS and BMLM are supported by CNPq. Part of the work of BBA is supported by the Fundação José Silveira, Salvador, Bahia, Brazil. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Compliance with ethical guidelines

Competing interests The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Laboratório Integrado de Microbiogia e Imunoregulação (LIMI), Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz (FIOCRUZ), Salvador, Brazil
(2)
Faculdade de Medicina, Universidade Federal da Bahia, Salvador, Brazil
(3)
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil
(4)
Universidade do Estado do Amazonas, Manaus, Brazil
(5)
Instituto de Investigação em Imunologia, Instituto Nacional de Ciência e Tecnologia, São Paulo, Brazil

References

  1. WHO (2014) World Malaria Report 2014. World Health Organization, GenevaGoogle Scholar
  2. Gubler DJ (2002) The global emergence/resurgence of arboviral diseases as public health problems. Arch Med Res 33:330–342View ArticlePubMedGoogle Scholar
  3. Gubler DJ (2002) Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 10:100–103View ArticlePubMedGoogle Scholar
  4. Abbasi A, Butt N, Sheikh QH, Bhutto AR, Munir SM, Ahmed SM (2009) Clinical features, diagnostic techniques and management of dual dengue and malaria infection. J Coll Physicians Surg Pak 19:25–29PubMedGoogle Scholar
  5. Baba M, Logue CH, Oderinde B, Abdulmaleek H, Williams J, Lewis J et al (2013) Evidence of arbovirus co-infection in suspected febrile malaria and typhoid patients in Nigeria. J Infect Dev Ctries 7:51–59View ArticlePubMedGoogle Scholar
  6. Epelboin L, Hanf M, Dussart P, Ouar-Epelboin S, Djossou F, Nacher M et al (2012) Is dengue and malaria co-infection more severe than single infections? A retrospective matched-pair study in French Guiana. Malar J 11:142PubMed CentralView ArticlePubMedGoogle Scholar
  7. Faruque LI, Zaman RU, Alamgir ASM, Gurley ES, Haque R, Rahman M et al (2012) Hospital-based prevalence of malaria and dengue in febrile patients in Bangladesh. Am J Trop Med Hyg 86:58–64PubMed CentralView ArticlePubMedGoogle Scholar
  8. Hati AK, Bhattacharjee I, Mukherjee H, Bandyopadhayay B, Bandyopadhyay D, De R et al (2012) Concurrent dengue and malaria in an area in Kolkata. Asian Pac J Trop Med 5:315–317View ArticlePubMedGoogle Scholar
  9. Magalhaes BML, Alexandre MAA, Siqueira AM, Melo GC, Gimaque JBL, Bastos MS et al (2012) Clinical profile of concurrent dengue fever and Plasmodium vivax malaria in the Brazilian Amazon: case series of 11 hospitalized patients. Am J Trop Med Hyg 87:1119–1124PubMed CentralView ArticlePubMedGoogle Scholar
  10. Magalhães BML, Siqueira AM, Alexandre MAA, Souza MS, Gimaque JB, Bastos MS et al (2014) P. vivax malaria and dengue fever co-infection: a cross-sectional study in the Brazilian Amazon. PLoS Negl Trop Dis 8:e3239PubMed CentralView ArticlePubMedGoogle Scholar
  11. Mohapatra MK, Patra P, Agrawala R (2012) Manifestation and outcome of concurrent malaria and dengue infection. J Vector Borne Dis 49:262–265PubMedGoogle Scholar
  12. Bin Mushtaq M, Qadri MI, Rashid A (2013) Concurrent infection with dengue and malaria: an unusual presentation. Case Rep Med 2013:520181Google Scholar
  13. Park S-H, Lee M-J, Baek J-H, Lee W-C (2011) Epidemiological aspects of exotic malaria and dengue fever in travelers in Korea. J Clin Med Res 3:139–142PubMed CentralPubMedGoogle Scholar
  14. Santana VDS, Lavezzo LC, Mondini A, Terzian ACB, de Bronzoni RVM, Rossit ARB et al (2010) Concurrent dengue and malaria in the Amazon region. Rev Soc Bras Med Trop 43:508–511View ArticleGoogle Scholar
  15. Shah I, Katira B (2007) Clinical and laboratory profile of dengue, leptospirosis and malaria in children: a study from Mumbai. Arch Dis Child 92:561PubMed CentralView ArticlePubMedGoogle Scholar
  16. Talarmin A, Peneau C, Dussart P, Pfaff F, Courcier M, de Rocca-Serra B, Sarthou JL (2000) Surveillance of dengue fever in French Guiana by monitoring the results of negative malaria diagnoses. Epidemiol Infect 125:189–193PubMed CentralView ArticlePubMedGoogle Scholar
  17. da Silva-Nunes M, dos Malafronte RS, de Luz BA, de Souza EA, Martins LC, Rodrigues SG et al (2006) The acre project: the epidemiology of malaria and arthropod-borne virus infections in a rural Amazonian population. Cad Saude Publica 22:1325–1334View ArticlePubMedGoogle Scholar
  18. Thaha M, Pranawa, Yogiantoro M, Tanimoto M, Tomino Y (2008) Acute renal failure in a patient with severe malaria and dengue shock syndrome. Clin Nephrol 70:427–430View ArticlePubMedGoogle Scholar
  19. Yong KP, Tan BH, Low CY (2012) Severe falciparum malaria with dengue coinfection complicated by rhabdomyolysis and acute kidney injury: an unusual case with myoglobinemia, myoglobinuria but normal serum creatine kinase. BMC Infect Dis 12:364PubMed CentralView ArticlePubMedGoogle Scholar
  20. Arias J, Valero N, Mosquera J, Montiel M, Reyes E, Larreal Y et al (2014) Increased expression of cytokines, soluble cytokine receptors, soluble apoptosis ligand and apoptosis in dengue. Virology 452–453:42–51View ArticlePubMedGoogle Scholar
  21. Bozza FA, Cruz OG, Zagne SMO, Azeredo EL, Nogueira RMR, Assis EF et al (2008) Multiplex cytokine profile from dengue patients: MIP-1beta and IFN-gamma as predictive factors for severity. BMC Infect Dis 8:86PubMed CentralView ArticlePubMedGoogle Scholar
  22. Kumar Y, Liang C, Bo Z, Rajapakse JC, Ooi EE, Tannenbaum SR (2012) Serum proteome and cytokine analysis in a longitudinal cohort of adults with primary dengue infection reveals predictive markers of DHF. PLoS Negl Trop Dis 6:e1887PubMed CentralView ArticlePubMedGoogle Scholar
  23. Maneekan P, Leaungwutiwong P, Misse D, Luplertlop N (2013) T helper (Th) 1 and Th2 cytokine expression profile in dengue and malaria infection using magnetic bead-based bio-plex assay. Southeast Asian J Trop Med Public Health 44:31–36PubMedGoogle Scholar
  24. Mendonça VRR, Queiroz ATL, Lopes FM, Andrade BB, Barral-Netto M (2013) Networking the host immune response in Plasmodium vivax malaria. Malar J 12:69PubMed CentralView ArticlePubMedGoogle Scholar
  25. Andrade BB, Reis-Filho A, Souza-Neto SM, Clarêncio J, Camargo LMA, Barral A et al (2010) Severe Plasmodium vivax malaria exhibits marked inflammatory imbalance. Malar J 9:13PubMed CentralView ArticlePubMedGoogle Scholar
  26. Andrade BB, Barral-Netto M (2011) Biomarkers for susceptibility to infection and disease severity in human malaria. Mem Inst Oswaldo Cruz 106(Suppl):70–78View ArticlePubMedGoogle Scholar
  27. Kuno G, Gómez I, Gubler DJ (1987) Detecting artificial anti-dengue IgM immune complexes using an enzyme-linked immunosorbent assay. Am J Trop Med Hyg 36:153–159PubMedGoogle Scholar
  28. WHO (2010) Guidelines for the treatment of malaria, 2nd edn. World Health Organization, GenevaGoogle Scholar
  29. Mourão MPG, Lacerda MVG, Macedo VO, Santos JB (2007) Thrombocytopenia in patients with dengue virus infection in the Brazilian Amazon. Platelets 18:605–612View ArticlePubMedGoogle Scholar
  30. Coelho HCC, Lopes SCP, Pimentel JPD, Nogueira PA, Costa FTM, Siqueira AM et al (2013) Thrombocytopenia in Plasmodium vivax malaria is related to platelets phagocytosis. PLoS One 8:e63410PubMed CentralView ArticlePubMedGoogle Scholar
  31. Lacerda MVG, Mourão MPG, Coelho HCC, Santos JB (2011) Thrombocytopenia in malaria: who cares? Mem Inst Oswaldo Cruz 106(Suppl):52–63View ArticlePubMedGoogle Scholar
  32. Kutsuna S, Hayakawa K, Kato Y, Fujiya Y, Mawatari M, Takeshita N et al (2014) The usefulness of serum C-reactive protein and total bilirubin levels for distinguishing between dengue fever and malaria in returned travelers. Am J Trop Med Hyg 90:444–448PubMed CentralView ArticlePubMedGoogle Scholar
  33. Espina LM, Valero NJ, Hernández JM, Mosquera JA (2003) Increased apoptosis and expression of tumor necrosis factor-alpha caused by infection of cultured human monocytes with dengue virus. Am J Trop Med Hyg 68:48–53PubMedGoogle Scholar
  34. Levy A, Valero N, Espina LM, Añez G, Arias J, Mosquera J (2010) Increment of interleukin 6, tumour necrosis factor alpha, nitric oxide, C-reactive protein and apoptosis in dengue. Trans R Soc Trop Med Hyg 104:16–23View ArticlePubMedGoogle Scholar
  35. Kurane I, Innis BL, Nimmannitya S, Nisalak A, Meager A, Janus J et al (1991) Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue. J Clin Invest 88:1473–1480PubMed CentralView ArticlePubMedGoogle Scholar
  36. Gagnon SJ, Mori M, Kurane I, Green S, Vaughn DW, Kalayanarooj S et al (2002) Cytokine gene expression and protein production in peripheral blood mononuclear cells of children with acute dengue virus infections. J Med Virol 67:41–46View ArticlePubMedGoogle Scholar
  37. Mendonça VR, Souza LC, Garcia GC, Magalhães BM, Lacerda MV, Andrade BB et al (2014) DDX39B (BAT1), TNF and IL6 gene polymorphisms and association with clinical outcomes of patients with Plasmodium vivax malaria. Malar J 13:278PubMed CentralView ArticlePubMedGoogle Scholar
  38. Rachman A, Rinaldi I (2006) Coagulopathy in dengue infection and the role of interleukin-6. Acta Med Indones 38:105–108PubMedGoogle Scholar
  39. Huang Y-H, Lei H-Y, Liu H-S, Lin Y-S, Chen S-H, Liu C-C et al (2003) Tissue plasminogen activator induced by dengue virus infection of human endothelial cells. J Med Virol 70:610–616View ArticlePubMedGoogle Scholar
  40. Mendonça VRR, Queiroz ATL, Lopes FM, Andrade BB, Barral-Netto M (2013) Networking the host immune response in Plasmodium vivax malaria. Malar J 12:69PubMed CentralView ArticlePubMedGoogle Scholar
  41. Perkins DJ, Weinberg JB, Kremsner PG (2000) Reduced interleukin-12 and transforming growth factor-b1 in severe childhood malaria : relationship of cytokine balance with disease severity. J Infect Dis 182:988–992View ArticlePubMedGoogle Scholar
  42. Luty AJF, Perkins DJ, Lell B, Schmidt-ott R, Lehman LG, Luckner D et al (2000) Low interleukin-12 activity in severe Plasmodium falciparum malaria. Infect Immun 68:3909–3915PubMed CentralView ArticlePubMedGoogle Scholar
  43. Doolan DL, Hoffman SL (1999) IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model. J Immunol 163:884–892PubMedGoogle Scholar
  44. Marquet S, Doumbo O, Cabantous S, Poudiougou B, Argiro L, Safeukui I et al (2008) A functional promoter variant in IL12B predisposes to cerebral malaria. Hum Mol Genet 17:2190–2195View ArticlePubMedGoogle Scholar
  45. Chaturvedi UC, Agarwal R, Elbishbishi EA, Mustafa AS (2000) Cytokine cascade in dengue hemorrhagic fever: implications for pathogenesis. FEMS Immunol Med Microbiol 28:183–188View ArticlePubMedGoogle Scholar
  46. Basu A, Chaturvedi UC (2008) Vascular endothelium: the battlefield of dengue viruses. FEMS Immunol Med Microbiol 53:287–299View ArticlePubMedGoogle Scholar
  47. de-Oliveira-Pinto LM, Gandini M, Freitas LP, Siqueira MM, Marinho CF, Setúbal S et al (2012) Profile of circulating levels of IL-1Ra, CXCL10/IP-10, CCL4/MIP-1β and CCL2/MCP-1 in dengue fever and parvovirosis. Mem Inst Oswaldo Cruz 107:48–56View ArticlePubMedGoogle Scholar
  48. Berrios V, Kurane I, Ennis FA (1996) Immunomodulatory effects of IL-7 on dengue virus-specific cytotoxic CD4+ T cell clones. Immunol Invest 25:231–240View ArticlePubMedGoogle Scholar
  49. Andrade BB, Reis-Filho A, Souza-Neto SM, Raffaele-Netto I, Camargo LMA, Barral A et al (2010) Plasma superoxide dismutase-1 as a surrogate marker of vivax malaria severity. PLoS Negl Trop Dis 4:e650PubMed CentralView ArticlePubMedGoogle Scholar
  50. Hottz ED, Medeiros-de-Moraes IM, Vieira-de-Abreu A, de Assis EF, Vals-de-Souza R, Castro-Faria-Neto HC et al (2014) Platelet activation and apoptosis modulate monocyte inflammatory responses in dengue. J Immunol 193:1864–1872View ArticlePubMedGoogle Scholar
  51. Villar-Centeno LA, Díaz-Quijano FA, Martínez-Vega RA (2008) Biochemical alterations as markers of dengue hemorrhagic fever. Am J Trop Med Hyg 78:370–374PubMedGoogle Scholar

Copyright

© Mendonça et al. 2015

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.

Advertisement